Attached files
| file | filename |
|---|---|
| EX-23.1 - EXHIBIT 23.1 - Travere Therapeutics, Inc. | t1500483_ex23-1.htm |
| EX-21.1 - EXHIBIT 21.1 - Travere Therapeutics, Inc. | t1500483_ex21-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Travere Therapeutics, Inc. | t1500483_ex31-2.htm |
| EX-32.1 - EXHIBIT 32.1 - Travere Therapeutics, Inc. | t1500483_ex32-1.htm |
| EX-31.1 - EXHIBIT 31.1 - Travere Therapeutics, Inc. | t1500483_ex31-1.htm |
| EX-10.28 - EXHIBIT 10.28 - Travere Therapeutics, Inc. | t1500483_ex10-28.htm |
| EX-10.27 - EXHIBIT 10.27 - Travere Therapeutics, Inc. | t1500483_ex10-27.htm |
| EX-10.25 - EXHIBIT 10.25 - Travere Therapeutics, Inc. | t1500483_ex10-25.htm |
| EX-10.26 - EXHIBIT 10.26 - Travere Therapeutics, Inc. | t1500483_ex10-26.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Travere Therapeutics, Inc. | Financial_Report.xls |
| 10-K - FORM 10-K - Travere Therapeutics, Inc. | t1500483_10k.htm |
| EX-32.2 - EXHIBIT 32.2 - Travere Therapeutics, Inc. | t1500483_ex32-2.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
Retrophin, Inc.
New York, New York
We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-198648) and Registration Statement on Form S-8 (No. 333-200224) of Retrophin, Inc. of our report dated March 11, 2015, relating to the consolidated financial statements of Retrophin, Inc., which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
BDO USA, LLP
New York, New York
March 11, 2015
BDO USA, LLP, a Delaware limited liability partnership, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.
BDO is the brand name for the BDO network and for each of the BDO Member Firms.